Wearable digital biomarkers promise early disease detection but most still lack clinical validation
A review finds continuous glucose monitoring is the one clear success among wearable digital biomarkers; most others remain in early validation.
Summary
Digital biomarkers are objective measures of body function and behavior collected by wearables and other digital tools. They could allow earlier detection and continuous monitoring of chronic diseases such as diabetes, heart disease, lung disease, brain disorders and mental illness. This review from Charité Berlin surveys progress across those fields. Continuous glucose monitoring in diabetes is the clear success story that has moved into routine clinical use. In cardiology, respiratory medicine and neurology, digital biomarkers sit at varying stages of validation, and most in internal medicine, neurology and mental health are still early. The authors name the barriers: too little testing in diverse populations, systems that cannot talk to each other, weak links to electronic health records, difficulty combining multiple data streams, immature regulatory pathways, and unequal access worldwide. They argue that turning consumer self-tracking into clinically trusted tools needs multicenter validation, shared standards and open data models.
Detailed Summary
Chronic non-communicable diseases are the leading cause of illness and death worldwide, and catching them early is central to extending healthspan. Digital biomarkers, meaning objective and quantifiable physiological or behavioral measures gathered through digital tools such as wearables, offer a way to assess health continuously in real life rather than in occasional clinic visits.
This narrative review from the Institute of Medical Informatics at Charité - Universitätsmedizin Berlin and the Hasso Plattner Institute examines advances across endocrinology, cardiology, respiratory medicine, neurology and mental health. It focuses on wearable technologies that capture real-world behavior and physiology over time.
The evidence is uneven. Continuous glucose monitoring in diabetes is presented as the example of successful clinical translation. Digital biomarkers in cardiology, respiratory medicine and neurology are at varying stages of validation and adoption, and most across internal medicine, neurology and mental health remain in early validation. The authors identify several barriers: limited validation in diverse populations, lack of interoperability, insufficient integration with electronic health records, difficulty synthesizing multimodal data, and underdeveloped regulatory pathways. Equity is also a concern, since infrastructure, affordability and capacity-building needs differ across the world.
The authors conclude that closing the gap between consumer self-tracking and clinically validated, guideline-compatible digital biomarkers requires rigorous multicenter validation, standardized interfaces, open data models, secure and ethical data infrastructure, and equitable design. Coordinated effort on these points is needed before digital biomarkers can reliably improve prevention, diagnosis and management of chronic disease.
The main caveat is that this is a review, not new trial data, and this summary is based only on the abstract. It does not quantify performance of specific devices, so readers should treat consumer metrics as promising but largely unvalidated outside of glucose monitoring.
Key Findings
- Continuous glucose monitoring in diabetes is the reviewed example of successful clinical translation of a digital biomarker.
- Digital biomarkers in cardiology, respiratory medicine and neurology are at varying stages of validation and adoption.
- Most digital biomarkers in internal medicine, neurology and mental health remain in early validation stages.
- Barriers include limited diverse-population validation, poor interoperability, weak EHR integration, multimodal data challenges and immature regulation.
- Equity gaps persist because infrastructure and affordability differ globally.
Methodology
Narrative review covering digital biomarkers in endocrinology, cardiology, respiratory medicine, neurology and mental health, centered on wearables. The abstract does not describe a search strategy, number of studies or evidence grading. No new data were collected.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The review is narrative, with no stated systematic methods or quantitative performance data for specific devices. Conclusions on validation stage are the authors' assessment and not tested in a new study.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
